A Phase I Trial of the Optune NovoTTF-200A System in Pediatric Patients With High-grade Glioma and Ependymoma
Clinical Trial Information
Trial Contact: El-Shami, Jessica; Leffin, Melissa; Spinelli, Jennifer; Cevallos, Claudia
To determine the safety and tolerability of the Optune NovoTTF-200A
System when used alone in pediatric patients with recurrent high-grade
gliomas and ependymomas.
• Age >=5 years and
• Patients must have a minimum head circumference of 44 cm
• Diagnosis: Patients must have either a histologically- or cytologically-confirmed
supratentorial highgrade glioma or supratentorial ependymoma.